UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
This intro provides practical steps to handle overspending, including assessing where expenses exceeded plans, trimming nonessential costs, and rebalancing budget categories.
10,154 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Investors chasing a gold tilt in their IRAs may face tax bites that trim gains more than expected. The IRS treats phy...
Four AI models were asked to compare a $10,000 XRP bet with a $10,000 Nvidia wager by 2030, revealing divergent paths...
AMD reported robust Q1 2026 results, with data center revenue surging and strategic AI partnerships signaling a durab...
Palo Alto Networks is set to report fiscal Q3 after the close, with investors eyes on growth guidance and the CyberAr...
A CNBC program features a tech CEO who says AI will replace junior staff and urges a tax on automation, triggering a ...
A sudden price collapse in a toll-tech stock creates a rare chance for patient investors. This guide explains how to ...
Oracle stock faces a pivotal moment as management doubles down on AI infrastructure while financing plans raise dilut...
New 2026 guidance shows high earners with million+ 401(k)s can still build tax-free Roth assets through after-tax con...
Two giants of the ETF world—FNCL and VFH—offer broad exposure to U.S. financials. This guide breaks down costs, liqui...
An international investigation ties a fentanyl-linked chinese network tied to a Japan-based crypto scam to a counterf...
Cardano moves to public testing for a scaling upgrade while ADA slides and a wallet exploit tests user trust, widenin...